A balancing act: Microbe versus muscle

Sara E. Cosgrove; G. Ralph Corey

doi:10.1086/600040

A balancing act: Microbe versus muscle

Sara E. Cosgrove, G. Ralph Corey

School of Medicine

Research output: Contribution to journal › Comment/debate › peer-review

6 Scopus citations

Original language	English (US)
Pages (from-to)	181-183
Number of pages	3
Journal	Clinical Infectious Diseases
Volume	49
Issue number	2
DOIs	https://doi.org/10.1086/600040
State	Published - Jul 15 2009

ASJC Scopus subject areas

Microbiology (medical)
Infectious Diseases

Access to Document

10.1086/600040

Cite this

@article{069d391637844a11803e4b70c0a9496f,

title = "A balancing act: Microbe versus muscle",

author = "Cosgrove, {Sara E.} and Corey, {G. Ralph}",

note = "Funding Information: Potential conflicts of interest. S.E.C. is a coinvestigator on a study assessing the safety and efficacy of high doses of daptomycin that is funded by Cubist Pharmaceuticals, has received grant funding from Astellas Pharma and AdvanDx, has served as a consultant to Merck, and has served on advisory boards for Astellas/Theravance, Forest Pharmaceuticals, and Ortho-McNeil. G.R.C. has served as a consultant to AstraZeneca, Astellas, Cempra, Cerexa, Cubist, Innocoll, Merck, Pfizer, Shire, Skyline Ventures, and Theravance and has served on advisory boards of GlaxoSmithKline, Inhibitex, Johnson & Johnson, Merck, Ortho-McNeil, Pfizer, Forest, and Vicuron.",

year = "2009",

month = jul,

day = "15",

doi = "10.1086/600040",

language = "English (US)",

volume = "49",

pages = "181--183",

journal = "Clinical Infectious Diseases",

issn = "1058-4838",

publisher = "Oxford University Press",

number = "2",

}

TY - JOUR

T1 - A balancing act

T2 - Microbe versus muscle

AU - Cosgrove, Sara E.

AU - Corey, G. Ralph

N1 - Funding Information: Potential conflicts of interest. S.E.C. is a coinvestigator on a study assessing the safety and efficacy of high doses of daptomycin that is funded by Cubist Pharmaceuticals, has received grant funding from Astellas Pharma and AdvanDx, has served as a consultant to Merck, and has served on advisory boards for Astellas/Theravance, Forest Pharmaceuticals, and Ortho-McNeil. G.R.C. has served as a consultant to AstraZeneca, Astellas, Cempra, Cerexa, Cubist, Innocoll, Merck, Pfizer, Shire, Skyline Ventures, and Theravance and has served on advisory boards of GlaxoSmithKline, Inhibitex, Johnson & Johnson, Merck, Ortho-McNeil, Pfizer, Forest, and Vicuron.

PY - 2009/7/15

Y1 - 2009/7/15

UR - http://www.scopus.com/inward/record.url?scp=67651091951&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67651091951&partnerID=8YFLogxK

U2 - 10.1086/600040

DO - 10.1086/600040

M3 - Comment/debate

C2 - 19500038

AN - SCOPUS:67651091951

SN - 1058-4838

VL - 49

SP - 181

EP - 183

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

IS - 2

ER -

A balancing act: Microbe versus muscle

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this